Abstract
1196P - Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have